Genes,
Год журнала:
2024,
Номер
15(12), С. 1591 - 1591
Опубликована: Дек. 11, 2024
The
immune
repertoire
(IR)
is
a
term
that
defines
the
combined
unique
genetic
rearrangements
of
antigen
receptors
expressed
by
B
and
T
lymphocytes.
IR
determines
ability
system
to
identify
respond
foreign
antigens
while
preserving
tolerance
host
antigens.
When
disrupted,
development
autoimmune
diseases
can
occur
due
attack
self-antigens.
Recent
technical
advances
in
profiling
allowed
identification
common
patterns
shared
antigen-binding
sequences
diverse
array
diseases.
However,
there
no
current
literature
date
evaluates
findings
skin
inflammatory
conditions.
In
this
review,
we
provide
an
overview
past
research
various
dermatologic
Enriching
our
understanding
IRs
these
conditions
critical
for
pathophysiology
behind
disease
onset
progression.
Furthermore,
B-cell
T-cell
will
help
devise
therapeutic
treatments
hopes
restoring
preventing
Rheumatology Science and Practice,
Год журнала:
2024,
Номер
62(3), С. 262 - 279
Опубликована: Июнь 26, 2024
Autoimmunity
is
a
pathological
process
associated
with
violation
of
immunological
tolerance
to
normal
structural
components
the
body
(autoantigens),
predominance
active
(adaptive)
immunity
and
manifested
by
hyperproduction
autoantibodies.
Systemic
autoimmune
rheumatic
diseases
(SARDs)
are
among
most
common
severe
nosological
forms
this
pathology
autoimmunity.
Problems
pharmacotherapy
SARDs
subject
intensive
research.
At
beginning
21st
century,
more
than
20
biologic
agents
were
developed
for
treatment
rheumatoid
arthritis
–
monoclonal
antibodies
(mAbs)
recombinant
proteins
that
control
inflammation
overproduction
“pro-inflammatory”
cytokines,
use
which
has
dramatically
improved
results
pharmacotherapy.
However,
much
less
research
been
devoted
studying
possibilities
aimed
at
selective
suppression
“autoimmune”
component
pathogenesis
SADRs
uncontrolled
activation
B
cells
restoration
autoantigens.
In
spectrum
drugs
whose
mechanism
action
cells,
leading
place
occupied
rituximab
(RTM).
It
noteworthy
years
ago
(2004),
group
researchers
led
prof.
J.C.
Edwards
first
demonstrated
effectiveness
RTM
in
patients
RA,
was
soon
successfully
repositioned
treat
wide
range
SARDs.
A
major
achievement
CAR
(сhimeric
antigen
receptor)
T
cell
therapy,
refractory
hematological
tumors.
The
main
CART-cells
genetically
engineered
T-cell
receptor
recognizes
target
without
participation
histocompatibility
complex.
Although
limited,
extremely
impressive
data
regarding
high
remission
rates
have
obtained
adapting
CD19
CART-cell
therapy
systemic
lupus
erythematosus
(SLE)
other
standard
immunosuppressive
medications.
article
discusses
SLE
prospects
further
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Дек. 19, 2024
Systemic
lupus
erythematosus
(SLE)
and
nephritis
(LN)
are
debilitating
autoimmune
disorders
characterized
by
pathological
autoantibodies
production
immune
dysfunction,
causing
chronic
inflammation
multi-organ
damage.
Despite
current
treatments
with
antimalarial
drugs,
glucocorticoids,
immunosuppressants,
monoclonal
antibodies,
a
definitive
cure
remains
elusive,
highlighting
an
urgent
need
for
novel
therapeutic
strategies.
Recent
studies
indicate
that
chimeric
antigen
receptor
T-cell
(CAR-T)
therapy
has
shown
promising
results
in
treating
B-cell
malignancies
may
offer
significant
breakthrough
non-malignant
conditions
like
SLE.
In
this
paper,
we
aim
to
provide
in-depth
analysis
of
the
advancements
CAR-T
SLE,
focusing
on
its
potential
revolutionize
treatment
complex
disease.
We
explore
fundamental
mechanisms
cell
action,
rationale
application
immunological
underpinnings
also
summarize
clinical
data
safety
efficacy
anti-CD19
anti-B
maturation
(BCMA)
cells
targeting
B-cells
discuss
implications
these
findings
improve
outcomes
severe
or
refractory
SLE
cases.
The
integration
into
paradigm
presents
new
horizon
autoimmunity
research
practice.
This
review
underscores
continued
exploration
optimization
strategies
address
unmet
needs
patients.
Cells,
Год журнала:
2025,
Номер
14(3), С. 210 - 210
Опубликована: Янв. 31, 2025
Systemic
lupus
erythematosus
(SLE)
is
a
systemic
autoimmune
disease
affecting
all
organ
systems.
The
preferentially
affects
females
of
childbearing
age.
It
runs
variable
course.
may
run
mild
course
that
never
lead
to
severe
and
manifestations
from
critical
However,
it
also
an
undulating
with
periods
disease.
as
disease,
quickly
deteriorating
multiple
Various
immune
pathways
related
both
the
innate
adaptive
response
are
involved
in
pathogenesis
SLE.
drugs
have
been
developed
targeting
cellular
molecular
targets
these
pathways.
Interferons
SLE,
various
target
this
pathway.
T
B
lymphocytes
pathophysiology
treatment
modalities
available
for
These
include
biologic
agents
lymphocytes.
some
patients
refractory
modalities.
For
patients,
cell-based
therapies
be
used.
Hematopoietic
stem
cell
transplantation
involving
autologous
cells
option
Mesenchymal
applied
Chimeric
antigen
receptor
(CAR)-T
therapy
novel
used
SLE
management.
This
method
holds
major
promise
management
diseases
and,
particular,
Major
hurdles
overcome
logistics
involved,
well
need
specialized
facilities.
review
focuses
on
system.
Biomolecules,
Год журнала:
2025,
Номер
15(3), С. 332 - 332
Опубликована: Фев. 25, 2025
Type
1
diabetes
(T1D)
is
an
autoimmune
disease
that
affects
estimated
30
million
people
worldwide
and
results
in
a
lifelong
dependency
of
exogenous
insulin
treatments.
While
T1D
characterized
by
T-cell
driven-destruction
the
insulin-secreting
β
cells,
B
lymphocytes
play
key
role
islet–immune
interface.
cells
are
essential
intermediary
between
islet
other
immune-cell
populations.
Through
antigen
presentation,
cytokine
secretion,
antibody
production,
activating
autoreactive
islet-specific
T
thus
potentiating
pancreatic
inflammation
early
stages
T1D.
Despite
this,
their
development
remains
understudied
feature
with
significant
therapeutic
potential.
Herein,
we
will
discuss
current
knowledge
islet–immune-cell
interface
within
through
lens
lymphocytes.
We
also
consider
gaps
may
be
limiting
further
opportunities.
